IGC Pharma vs Neuphoria Therapeutics
IGC and NEUP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IGC and NEUP compare
Neuphoria Therapeutics scores higher on the StockData Score (5 against 2 for IGC Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IGC | NEUP |
|---|---|---|
| Size and price | ||
| Market cap | $18.2M | – |
| Share price | $0.176 | $2.55 |
| Change, 1 year | −51.9% | −48.0% |
| Change, 5 years | −87.7% | – |
| Beta (5Y) | 0.59 | 0.86 |
| Employees | 67 | 7 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.2× | – |
| P/B | 2.8× | – |
| Fair value | $0.161 | – |
| Margin of safety | −9.1% | – |
| Growth | ||
| Revenue growth (TTM) | −15.4% | – |
| Profitability | ||
| Gross margin | 21.9% | – |
| Operating margin | −987% | – |
| Net margin | −702% | – |
| Return on equity | −113% | −61.7% (better) |
| Return on invested capital | −136% (better) | −273% |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.00 |
| Current ratio | 0.42 | 27.85 (better) |
| Altman Z-score | −19.52 | – |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 5.1% | 36.8% |
| Held by insiders | 13.2% | – |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 0.44% | – |
Go deeper
- IGC stock overview
- IGC income statement
- IGC valuation and score
- NEUP stock overview
- NEUP income statement
- NEUP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.